ATARA BIOTHERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $32.7M | $-85.4M | $-276.1M | $-228.3M | $-340.1M | $-306.6M | $-291.0M | $-230.7M |
| Depreciation & Amortization | $2.1M | $5.1M | $4.8M | $5.7M | $9.3M | $8.3M | $7.1M | $3.7M |
| Depreciation | $400.0K | $2.7M | $3.7M | $4.7M | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $9.8M | $27.0M | $45.4M | $53.8M | $53.9M | $51.4M | $51.7M | $33.8M |
| Net Cash from Operating Activities | $-50.9M | $-68.7M | $-193.0M | $-270.4M | $-220.5M | $-180.8M | $-235.6M | $-179.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $246.0K | $1.2M | $4.2M | $10.6M | $4.5M | $5.7M | $35.9M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $18.1M | $8.6M | $123.9M | $203.0M | $22.3M | $-120.7M | $60.5M | $-196.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $16.1M | $59.3M | $2.0M | $53.1M | $103.9M | $427.6M | $188.8M | $357.5M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-50.9M | $-69.0M | $-194.2M | $-274.6M | $-231.1M | $-185.3M | $-241.4M | $-215.7M |